# Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD)

> **NCT04968184** · PHASE3 · TERMINATED · sponsor: **KBP Biosciences** · enrollment: 652 (actual)

## Conditions studied

- Chronic Kidney Diseases

## Interventions

- **DRUG:** Placebo
- **DRUG:** KBP-5074

## Key facts

- **NCT ID:** NCT04968184
- **Lead sponsor:** KBP Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-11-05
- **Primary completion:** 2024-01-30
- **Final completion:** 2024-07-10
- **Target enrollment:** 652 (ACTUAL)
- **Why stopped:** Interim futility analysis showed primary endpoint not achieved
- **Last updated:** 2025-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04968184

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04968184, "Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04968184. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*